The invention relates to compounds of formula (I):
wherein R1, R2, R3, R4, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.
本发明涉及式 (I) 化合物:
其中 R1、R2、R3、R4、L 和 A 如说明书和权利要求书中所定义,或其药学上可接受的盐具有 mTOR 激酶
抑制剂活性。本发明还涉及包括式(I)化合物或其药学上可接受的盐的药物组合物,以及式(I)化合物或其药学上可接受的盐在治疗中的用途,包括治疗具有mTOR激酶
抑制剂活性的疾病或病症,特别是特发性肺纤维化的治疗。